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Prostate cancer is the most common malignancy and the second
leading cause of cancer-related deaths among men in the US and
the UK (Shibata et al, 1998). Increased awareness of the disease
and improved methods for early detection allow treatment to start
when the tumour is still androgen-sensitive. Androgen ablation
remains the most effective therapy for the treatment of prostate
cancer. However, studies conducted by the National Cancer
Institute (Crawford et al, 1992) and the European Organization for
Research and Treatment of Cancer (Denis et al, 1994) showed that
while the ablation of testicular androgens by chemical castration
was an effective treatment option, inhibiting the action of adrenal
androgens with anti-androgens significantly prolonged the
survival of subset of prostate cancer patients. Therefore, complete
instead of partial withdrawal of androgens could be an effective
approach for the treatment of prostate cancer.
With this aim, our laboratory has designed enzyme inhibitors to
block androgen synthesis from all sites (Ling et al, 1997; Njar et
al, 1998). Steroidal 17a-hydroxylase/C17,20-lyase (P450c17) (EC
1.14.99.0) was selected as the target enzyme for inhibition, as this
is a key regulatory enzyme of androgen synthesis. P450c17 catal-
yses two sequential reactions in the steroid biosynthetic pathway
and converts pregnenolone and progesterone to the C-19 andro-
gens, dehydroepiandrosterone and androstenedione respectively.
This enzyme has an identical amino acid sequence in testicular and
adrenal tissues (Chung et al, 1987). Therefore, P450c17 inhibitors
would be equally effective at both sites. In order to evaluate the
effectiveness of these inhibitors we developed a multi-step system,
which utilized the LNCaP human prostate cancer cell line. LNCaP
cells remain the only androgen receptor (AR)-positive prostate
cancer cell line, that can be readily grown in tissue culture
(Horoszewicz et al, 1983). These cells respond to androgens with
increased cell proliferation and elevated expression of prostate
specific antigen (PSA) (Berns et al, 1993). LNCaP cells at early
passages are not only androgen-responsive, but also androgen-
dependent (Pousette et al, 1997). This is similar to the situation in
most tumours of prostatic cancer patients, which are initially
highly responsive and dependent on androgens. Although LNCaP
cells have a mutated AR (Veldscholte et al, 1990), this cell line has
been used extensively in research on the causes, treatment and
prevention of prostate cancer (Weber et al, 1997). Therefore, we
employed LNCaP cells as a model for evaluating the effectiveness
of our new inhibitors of androgen synthesis.
In this study the compounds selected for evaluation were two
groups of azolyl steroids. The first group has a double bond at the
fifth carbon atom in the steroid molecule: the D5-non-competitive
inhibitors (D5NCIs) of P450c17 are VN/63-1, VN/85-1 and
VN/87-1. The second group are their corresponding D4 derivatives
(D4NCIs), and are VN/107-1, VN/108-1 and VN/109-1, which
have a double bond at the fourth carbon atom in the steroid mole-
cule (Figure 1) (Njar et al, 1998).
Here we report on the application of LNCaP-CYP17-transfected
cells for determining the inhibitory potencies of the new
compounds against the P450c17 enzyme. As we have reported
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suggested that the D5NCIs may also be acting as anti-androgens. We further evaluated our inhibitors in male severe combined immuno-
deficient mice bearing LNCaP tumour xenografts. In this model VN/85-1 was as effective as finasteride at inhibiting tumor growth (26% and
28% inhibition, respectively) and the inhibitory effect of VN/87-1 was similar to that of castration (33% and 36% inhibition respectively). These
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mammalian cells for expression of functional P450c17 enzyme,
and the IC50 values of azolyl steroids obtained using this model
were comparable to those obtained with human testicular micro-
somes (Grigoryev et al, 1999). We also utilized wild-type LNCaP
prostatic carcinoma cells for evaluating the direct effects of new
azolyl steroids on proliferation of these cells in vitro and in vivo.
MATERIALS AND METHODS
Materials
The human prostate cancer cell line LNCaP was obtained from the
American Type Culture Collection (Rockville, MD, USA). RPMI-
1640 medium, trypsin–EDTA (0.25%/0.02%), penicillin/strepto-
mycin (P/S), geniticin (G418), and LipofectAMINE were from
Gibco-BRL (Grand Island, NY, USA). Fetal bovine serum (FBS)
was obtained from Summit Biotechnology Inc. (Fort Collins, CO,
USA) and steroid-free FBS was prepared as described previously
(Klus et al, 1996). Phenol red free IMEM and trypsin–versine were
purchased from Biofluids Inc. (Rockville, MD, USA). Chloroform
and acetonitrile were purchased from JT Baker, Inc (Phillipsburg,
NJ, USA). Hydroxypropyl cellulose (HPC) was purchased from
Sigma Chemical Co. (St Louis, MO, USA). The PSA enzyme-
linked immunusorbent assay (ELISA) kit was from DSL Inc.
(Webster, TX, USA). Matrigel was generously supplied by Dr
Hynda Kleinman (NIH, Bethesda, MD, USA).
Inhibitors of androgen synthesis: VN/63-1, VN/85-1, VN/87-1,
VN/107-1, VN/108-1 and VN/109-1 were synthesized in our labo-
ratory as previously described (Njar et al, 1998). Ketoconazole
was a gift from Dr Y Ling (Beijing Medical University, Beijing,
China). Finasteride was kindly provided by Merck Research
Laboratories (Rahway, NJ, USA). Flutamide was purchased from
Sigma Chemical Co. [21-3H]17a-Hydroxypregnenolone ([21-
3H]17aOHP5: specific activity 13.61 mCi mmol–1) was prepared in
our laboratory as described previously (Njar et al, 1998).
Metribolone [17a-methyl-3H]-R1881 ([3H]-R1881: specific
activity 86 Ci mmol–1) was purchased from Dupont NEN (Boston,
MA, USA).
Methods
Transfection of LNCaP prostate cancer cells with
pCDNA3Hmod17His
LNCaP cells (passage number 26–30) were grown in RPMI-1640
medium containing 10% FBS and 1% P/S. LNCaP cells were
transfected with the pCDNA3Hmod17His construct as we have
previously described (Grigoryev et al, 1999) and grown in the
same medium supplemented with 750 mg ml–1 geniticin (G418).
The surviving colonies were maintained in selective media and
tested twice a month for C17,20-lyase activity as described in the
following section. After 3 months (16 passages) the transfectant
cell line with the greatest C17,20-lyase activity was selected
(LNCaP-CYP17) and used for evaluation of IC50 values of the
prospective inhibitors.
[3H]-acetic acid releasing assay with LNCaP-CYP17
The acetic acid releasing assay (AARA) was performed essentially
as described previously (Grigoryev et al, 1999). Briefly, LNCaP-
CYP17 cells were grown in 6-well tissue culture plates to 80%
confluency. Cells were washed with Dulbecco’s phosphate-
buffered saline (DPBS), and incubated with steroid-free medium
(1 ml) containing 0.5–20 mM of [21-3H]17a-OHP5. This substrate
is converted to DHEA and [3H]acetic acid is released during
cleavage of the C-21 side chain. Cold 17a-hydroxypregnenolone
(17a-OHP5, 1 mM) was added to control wells for detection of
non-specific substrate conversion. After a 16-h incubation at 37°C,
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Figure 1 Chemical structures of azolyl steroid inhibitors of 17a-
hydroxylase/C17,20-lyase. Compounds are divided in two groups: D5 non-
competitive (left) and D4 non-competitive (right). All compounds in the same
group have a common base structure and differ in the azolyl group at carbon
position 17
Figure 2 Saturation curve of 17a-hydroxylase/C17,20-lyase enzyme and
Scatchard–Eadie plot (insert). LNCaP cells expressing the P450c17 enzyme
were treated with different concentrations of [213H]17a-hydroxypregnenolone
(0.5–20 mM). The specific activity was determined after incubation for 16 h at
37°C. Maximum activity (12.5 pmol h–1 10–5 cells) was reached at 7 mM
concentration and Km was estimated by using RADLIG software as 0.87 mM
(insert)624 DN Grigoryev et al
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medium was collected and the steroids were extracted with 2 ml of
chloroform at 4°C. The aqueous phase, which contains the
[3H]acetic acid, was collected, and charcoal suspension was added
to 2.5% final concentration. Following a 30-min incubation at 4°C,
an aliquot of the supernatant was removed and radioactivity
measured by liquid scintillation counting. Km and Vmax values were
calculated using RADLIG 40 software (Biosoft, Ferguson, MO,
USA). To determine the IC50 values of the test compounds, LNCaP
cells were incubated with medium (1 ml) containing 7 mM of
[21-3H]17a-OHP5 (the saturating concentration; Figure 2) and
different concentrations (1–100 nM) of the inhibitors. After a 16-h
incubation, the medium was analysed as described above and IC50
values were calculated.
Effects of the azolyl steroids and reference drugs on wild-
type LNCaP cell growth
LNCaP cell were transferred into steroid-free medium 3 days prior
to the start of all experiments. Steroid-free medium consisted of
phenol red-free IMEM supplemented with 5% steroid-free FBS
and 1% P/S. Cells were then plated into 24-well culture plates
(15 000 cells per well) in 1 ml of the same medium. After a 24-h
attachment period, the vehicle (ethanol) or selected inhibitors at
concentrations 0.5, 1.0, 2.5 and 5.0 mM were added to the triplicate
wells. Medium and treatments were changed every 72 h. After 9
days of treatment, the cells were removed with trypsin–EDTA and
counted in a Coulter counter (Coulter Electronics, Hialeah, FL,
USA). The effects of the inhibitors on testosterone (0.1 nM) or
DHT (0.03 nM) stimulated LNCaP cell growth were evaluated by
the same method. For determining toxicity of compounds tested,
LNCaP cells (105) were incubated in steroid-free media (1 ml)
containing 0.5–20 mM of the test inhibitors. After 3 days, cells
were collected and counted as described above. The toxicity of the
compound I-49 was used as a positive control (Klus et al, 1996).
Androgen receptor binding assays
Binding of [3H]R1881 to the AR in the presence of the azolyl
steroids and reference drugs was performed as described previ-
ously (Wong et al, 1995) with slight modifications. Briefly, 24-
well plates were pre-treated with poly-L-lysine (0.05 mg ml–1) for
30 min and dried. LNCaP cells were prepared as described above
and plated at 2–3 ´ 105 cells per well. After a 24-h incubation,
culture medium was replaced with serum-free, phenol red-free
IMEM containing 5 nM [3H]R1881. To determine non-specific
binding a 200-fold excess of cold R1881 was added to control
wells. The test compounds (5 mM) were added to triplicate wells.
Following a 2-h incubation at 37°C, the cells were washed twice
with ice-cold DPBS and solubilized with 0.5% sodium dodecyl
sulphate (SDS) and 20% glycerol in the same buffer. Extracts were
removed and cell associated [3H]R1881 was determined using a
scintillation counter.
Evaluation of the test compounds in male SCID mice
Male severe combined immunodeficient (SCID) mice were
purchased from Charles River Breeding Laboratories (Boston,
MA, USA). The animals were housed in a pathogen-free environ-
ment under controlled conditions of light and humidity and
received food and water ad libitum. LNCaP tumours were grown
subcutaneously (s.c.) in the mice essentially as described by Sato
et al (1997). Briefly, wild-type LNCaP cells were grown in routine
medium as described earlier. When 80% confluent, the cells were
scraped into DPBS, counted, and suspended in Matrigel (3 ´ 107
cells/ml). Male SCID mice were injected s.c. with 100 ml of the
cell suspension at one site on each flank. LNCaP tumours were
allowed to grow for 4–5 weeks following cell inoculation. The
mice were then grouped (six mice per group) for castration or
treatment with vehicle or the test inhibitors (50 mg kg–1 day–1).
Tumours were measured weekly for the 4 weeks of treatment and
tumour volumes were calculated using the formula 0.5236 ´ r1
2 ´
r2 (r1 < r2). At the end of the treatment period, the animals were
sacrificed by decapitation and blood collected. Serum was
obtained after centrifugation and stored at –80°C. Tumours were
excised, weighed and stored in liquid nitrogen.
Measurement of serum PSA, testosterone and DHT levels
Serum PSA concentrations were measured using a PSA ELISA kit
(DSL Inc). Before assay, serum was thawed and diluted 1:10 in
DPBS. PSA levels were determined in a 25 ml aliquot of diluted
serum according to the manufacturers protocol. For measurement
of serum testosterone and DHT levels, mouse serum was assayed
according to the manufacturer’s protocol with a 125I-testosterone
RIA kit and a 125I-DHT RIA kit respectively (both kits were
obtained from DSL Inc.). Radioactivity was counted using a
Packard Cobra II gamma counter.
RESULTS
Inhibition of P450c17 activity in LNCaP-CYP17 cells by
the azolyl steroids and reference drugs
The structures of compounds evaluated are shown in Figure 1. The
Vmax of P450c17 in LNCaP-CYP17 cells was determined by
AARA to be 11 pmol 10–5 cells h–1 and Km was 0.87 mM (Figure 2).
The effects of the inhibitors on P450c17 activity in this
mammalian expression system are shown in Table 1. The IC50
values of compounds tested were in the range 1–100 nM. The
D5NCI VN/85-1 and its D4 derivative VN/108-1 were the most
potent inhibitors of the enzyme activity, with IC50 values of 1.25
nM and 2.96 nM respectively. This is consistent with our previously
reported results obtained with human testicular microsomes and
P450c17-transformed bacteria (Grigoryev et al, 1999). The IC50
Table 1 Inhibition of human 17a-hydroxylase/C17,20-lyase and 5a-reductase
by novel azolyl steroids
Compound IC50 (nM ± s.e.m.)
C17,20-lyase 5a-reductase
Ketoconazole 80.7 ± 1.8 NI
Finasteride NI 33 ± 2.0
Flutamide NI NT
VN/63-1 47.1 ± 0.2 NI
VN/85-1 1.25 ± 0.44 NI
VN/87-1 7.97 ± 0.98 NI
VN/107-1 12.4 ± 1.1 152 ± 10.0
VN/108-1 2.96 ± 0.78 142 ± 5.0
VN/109-1 5.39 ± 0.12 198 ± 33.0
NI, the IC50 values are higher than 5000 nM; NT, not tested. The inhibitory
effects of the listed compounds on activity of the human 17a-
hydroxylase/C17,20-lyase expressed in LNCaP-CYP17 cells were determined
as described in Materials and Methods. Inhibition of 5a-reductase activity in
human prostatic microsomes was reported previously (Njar et al, 1998). The
inhibitory potency of the test compounds is expressed as IC50. Values from
three different experiments are expressed as mean ± s.e.m.values for all of the new azolyl steroids were in the range
1.25–47.1 nM, and these values are much lower than that of the
P450 inhibitor ketoconazole (80.7 nM). Table 1 also shows the
previously reported IC50 values of the compounds for human
prostatic 5a-reductase (Nnane et al, 1998). All of the D4NCIs were
effective against 5a-reductase but their IC50 values were four- to
sixfold higher than that of finasteride. However, the D5NCIs did
not inhibit 5a-reductase.
Effects of the azolyl steroids and reference drugs on
LNCaP cell growth
The abilities of the test compounds to inhibit proliferation in wild-
type LNCaP cells stimulated by 0.1 nM testosterone or 0.03 nM
DHT was examined. We have previously reported that these
concentrations of the androgens are most suitable for LNCaP
growth stimulation studies (Klus et al, 1996). Testosterone 
stimulated LNCaP cell proliferation by 5.8-fold compared to the
vehicle-treated control cells (Figure 3A). The growth stimulatory
effect of testosterone was completely inhibited by 1.0 mM of
VN/63-1 and VN/85-1, and by 2.5 mM of VN/87-1. VN/108-1 and
finasteride were equally as effective at 5-mM concentration.
VN/107-1 was ineffective against testosterone-stimulated cell
growth and VN/109-1 had a moderate inhibitory effect.
Ketoconazole was found to stimulate cell proliferation at low
concentrations. However, both ketoconazole and VN/109-1
elicited biphasic growth responses. The anti-androgen flutamide
inhibited testosterone stimulated cell growth by ~50% at concen-
trations of 2.5 and 5.0 mM (Figure 3A).
Cells were also treated with the inhibitors in the presence of
0.03 nM DHT. This concentration of androgen stimulated LNCaP
cell proliferation by 3.2-fold compared to vehicle-treated cells
(Figure 3B). DHT stimulation was completely blocked by 1.0 mM
of VN/63-1, VN/85-1 and finasteride; 2.5 mM of VN/87-1; and
5.0 mM of VN/108-1. VN/107-1 and VN/109-1 were again found
to be the least effective inhibitors of androgen-induced cell pro-
liferation. Ketoconazole and flutamide stimulated cell growth by
10–20% compared to DHT-treated cells (Figure 3B).
To investigate whether the compounds may be acting as anti-
androgens, LNCaP cells were treated with the inhibitors alone in
steroid-free media for 9 days (Figure 4). All of the D5NCIs inhib-
ited cell growth in a concentration-dependent manner by 40–60%.
In contrast, all of the D4NCIs stimulated cell growth by 1.5 to 2-
fold. Finasteride at concentrations of 1.0–5.0 mM inhibited cell
growth by 20–30%. High concentrations of ketoconazole (2.5 and
5.0 mM) stimulated cell growth by 30–40%. Flutamide stimulated
cell growth approximately sixfold in a biphasic manner (Figure 4).
None of the novel compounds were found to be toxic to the
LNCaP cells at the concentrations tested.
LNCaP androgen receptor binding assays
The ability of the test compounds to prevent binding of the
synthetic androgen R1881 to LNCaP AR was examined. LNCaP
cells were incubated in steroid-free media containing 5 nM
[3H]R1881 and 5 mM of the test compounds and reference drugs.
All of the D4NCIs were more potent than the anti-androgen
flutamide at displacing [3H]R1881 from the LNCaP AR.
Flutamide displaced 50% of [3H]R1881, while the D4NCIs
displaced 70–80% (Figure 5). The D5NCIs VN/63-1, VN/85-1 and
In vitro and in vivo effects of C17,20-lyase inhibitors 625
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Figure 3 Effects of the azolyl steroids and reference drugs on testosterone (A) and DHT (B) stimulated LNCaP cell proliferation. The ability of the compounds
to inhibit the stimulatory effects of 0.1 nM testosterone or 0.03 nM DHT on LNCaP cell proliferation was tested as described in Materials and Methods. The
columns represent the mean of the cell numbers in triplicate wells from three different experiments after incubation for 9 days. Cell number is expressed as a
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VN/87-1 displaced 50%, 40% and 30% of [3H]R1881 respectively.
Ketoconazole and finasteride displaced 17% and 20% of
[3H]R1881 respectively (Figure 5).
Effects of the inhibitors in LNCaP tumour growth in
male SCID mice
Male SCID mice bearing LNCaP tumour xenografts were treated
with the azolyl steroids (50 mg kg–1 day–1) for 4 weeks and the
tumour volumes were measured weekly. In each of the experi-
ments ketoconazole, finasteride and castration were used as refer-
ence groups. In the first experiment the effects of VN/85-1,
VN/87-1 and VN/108-1 on LNCaP tumour growth were examined
(Figure 6A). VN/108-1 inhibited LNCaP tumour growth by only
9%. VN/85-1 inhibited tumour growth by 25% and in this model
was as effective as finasteride, which inhibited tumour growth by
27%. VN/87-1 inhibited tumour growth by 33%, which was
similar to the result obtained with the castrated mice (36% growth
inhibition). These reductions in tumour volumes correlated with
final tumour weights (Figure 6B). Tumour weights in the castrated
group were the lowest (68% of control). Tumour weights in the
VN/87-1 group were reduced by 31% compared to the vehicle-
treated mice and were reduced by 22% and 27% in the animals
treated with finasteride and VN/85-1 respectively. Serum PSA
levels were significantly lower in the mice treated with castration,
finasteride, VN/87-1 (P < 0.02) VN/85-1 (P < 0.04) and surpris-
ingly VN/108-1 (P < 0.02) (Figure 6B). Serum androgen levels in
castrated mice and in the mice treated with VN/85-1, VN/87-1 and
VN/108-1 were significantly reduced (Table 2). Serum DHT levels
were also significantly lower in the mice treated with finasteride
(P < 0.01).
In the second experiment the effects of VN/63-1, VN/107-1 and
VN/109-1 on LNCaP tumour growth were examined (Figure 7A).
LNCaP tumour growth was found to be stimulated 110% by
VN/109-1, when compared to control mice. Neither VN/63-1,
VN/107 nor ketoconazole had any appreciable effects on the growth
of the tumours following 28 days of treatment. The only treatments
that reduced tumour volumes were finasteride (29% growth inhibi-
tion) and castration (33% growth inhibition). These results were also
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Figure 4 Effects of the azolyl steroids and reference drugs on LNCaP cell
proliferation in steroid-free medium. LNCaP cells were exposed to the test
compounds in steroid-free media. After 9 days, cells were collected and
counted as described in Materials and Methods. The columns represent the
mean of the cell numbers in triplicate wells from three different experiments.
Cell number is expressed as a percentage of the mean number in the control
wells. Values are expressed as mean ± s.e.m.
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Figure 5 Competition of the azolyl steroids with the synthetic androgen
R1881 for the LNCaP androgen receptor. LNCaP cells were incubated in
steroid-free media containing 5 nM of R1881 with or without 5 mM of the
inhibitors. After incubation for 2 h, medium was removed and cells were
washed with DPBS. Cells were collected and bound R1881 was determined
as described in Materials and Methods. The columns show the percent of
R1881 (pmol per cell) bound to the cells and are expressed as a percentage
of total bound R1881. Values from three different experiments are expressed
as mean ± s.e.m.
Table 2 Serum levels of testosterone and DHT in male SCID mice following
28 days of treatment with the azolyl steroids and reference drugs
Treatment group Testosterone (ng ml–1) DHT (pg ml–1)
Control 1.043 ± 0.120 243.8 ± 21.5
Castrate 0.286 ± 0.045a 162.0 ± 12.3c
Ketoconazole 1.526 ± 0.456 224.3 ± 31.9
Finasteride 1.389 ± 0.107 137.0 ± 7.7b
VN/85-1 0.141 ± 0.028a 143.7 ± 13.2b
VN/87-1 0.343 ± 0.042b 128.6 ± 4.9a
VN/108-1 0.081 ± 0.015b 122.1 ± 6.4a
aP < 0.001 versus control; bP < 0.01 versus control; cP < 0.05 versus control.reflected in final tumour weights (Figure 7B). Tumour weights in
the castrated group were reduced by 41%, and in the finasteride-
treated group by 28%. In agreement with the result obtained in the
first experiment, serum PSA levels were significantly lower in the
mice treated with castration and finasteride (P< 0.04). Serum testos-
terone levels were significantly reduced in the mice treated with
castration (P < 0.001) and VN/109-1 (P < 0.05); and significantly
higher in the mice treated with finasteride, which was expected
because inhibition of 5a-reductase often results in increased circu-
lating levels of testosterone (Gormley et al, 1992). Serum DHT
levels were significantly lower (P < 0.05) in the group treated with
VN/107-1 (Table 2).
DISCUSSION
There have been several reports on the importance of maximal
androgen ablation for the treatment of prostate cancer (Crawford et
al, 1989, 1992; Visakorpy et al, 1995). These studies reported that
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Figure 6 Effects of the VN/85-1, VN/87-1, VN/108-1 and reference drugs
on the growth of LNCaP tumour in male SCID mice and serum PSA levels.
LNCaP cells were inoculated s.c. into SCID mice and allowed to proliferate
as tumour xenografts to 300 mm3. Groups of 5–6 mice were injected daily
with the test compounds (50 mg kg–1 day–1). (A) Tumours were measured
weekly and percentage change in volumes were calculated. (B) After 28
days of treatment, mice were sacrificed, tumours were weighed and serum
PSA levels measured. The open bars represent the tumour weights (mg per
mouse) and closed bars represent mean serum concentrations of prostate
specific antigen (ng ml–1). Values are expressed as mean ± s.e.m. (*P < 0.04,
**P < 0.02)
Figure 7 Effects of the VN/63-1, VN/107-1, VN/109-1 and reference drugs
on the growth of LNCaP tumor in male SCID mice and serum PSA levels.
Procedures were the same as indicated in Figure 6628 DN Grigoryev et al
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while ablation of testicular androgens by chemical castration is an
effective treatment option, castration combined with anti-androgens
to inhibit the action of adrenal androgens significantly prolonged the
survival of prostate cancer patients. Moreover, patients who relapse
on anti-androgen therapy may experience a second response upon
anti-androgen withdrawal (Small et al, 1997). As an alternative
approach to inhibiting the production of androgens from all sites,
our laboratory has been developing inhibitors of P450c17, which is
a key regulatory enzyme of the androgen biosynthetic pathway
(Ling et al, 1997; Njar et al, 1998). P450c17 catalyses two sequen-
tial reactions in the steroid biosynthetic pathway. The 17a-
hydroxylase reaction converts pregnenolone and progesterone to
17a-hydroxypregnenolone (17a-OHP5) and 17a-hydroxyproges-
terone (17a-OHP4) respectively. Then, the C17,20-lyase reaction
converts 17a-OHP5 and 17a-OHP4 to the immediate androgen
precursors dehydroepiandrosterone and androstenedione respec-
tively. The known cytochrome P450 inhibitor ketoconazole has
activity against P450c17 and has been used for the treatment of
prostate cancer, both as a substitute for androgen ablation therapy
(Trachtenberg et al, 1984) and as an adjuvant to castration (Williams
et al, 1986). However, this drug has low P450c17 specificity, it
inhibits cortisol production and is associated with high hepato-
toxicity (Jubilerer et al, 1989). Nonetheless, Small et al (1997) have
reported that ketoconazole administration is beneficial to patients
with advanced prostate carcinoma who have relapsed from anti-
androgen (flutamide) therapy. Using LNCaP prostate cancer cells
transfected with the human P450c17 gene (CYP17), we determined
that some of our new azolyl steroids were 50- to 60 fold stronger
than ketoconazole at inhibiting P450c17 and that VN/85-1 and its
D4 counterpart VN/108-1 were the most potent inhibitors (Table 1).
Therefore, we hypothesized that these compounds would be effec-
tive for the treatment of prostate cancer.
In the present study we examined the abilities of several of our
novel azolyl steroids to inhibit the growth of LNCaP prostate
cancer cells in vitro and in vivo, and compared their effects to the
known prostate cancer drugs finasteride, flutamide and ketocona-
zole. The compounds tested were the D5NCIs, VN/63-1, VN/85-1
and VN/87-1, and their D4 counterparts, VN/107-1, VN/108-1 and
VN/109-1 (Njar et al, 1998). All of the D5NCIs, VN/108-1 and
finasteride showed concentration-dependent inhibitory effects on
testosterone stimulated LNCaP cell proliferation in culture, and
VN/63-1 and VN/85-1 were the most potent inhibitors of testos-
terone induced cell growth (Figure 3A). This inhibition was unex-
pected, because these compounds were designed as inhibitors of the
P450c17 enzyme, which is not expressed in LNCaP cells. The
antiproliferative effects of the D5NCIs could not be due to 5a-
reductase inhibition since these compounds have no effect on
5a-reductase activity in prostatic microsomes (Table 1) and
displayed the same growth inhibitory effects on DHT-stimulated as
on testosterone-stimulated LNCaP cell growth (Figure 3B). In addi-
tion, these effects were not due to a direct cytotoxic effect of the
compounds on LNCaP cells (data not shown). These results suggest
that, in addition to being potent inhibitors of P450c17, the D5NCIs
may have other as yet undefined activities. VN/107-1, unlike its D5
counterpart (VN/63-1), had no antiproliferative activity. VN/109-1
retained approximately the same activity as its D5 analogue
(VN/87-1) at concentrations of 0.5 and 1.0 mM, but had no
inhibitory activity at higher concentrations. The anti-androgen
flutamide, which has an androgenic effect on LNCaP cells (Wilding
et al, 1989) unexpectedly inhibited testosterone-stimulated but not
DHT-stimulated cell proliferation at high concentrations. This
effect could be due to an androgen-like effect of the drug. It has
been shown previously that LNCaP cells react to androgen stimula-
tion with a biphasic concentration-dependent response, and that
high concentrations of androgens can inhibit cell growth (De
Launoit et al, 1991). The addition of flutamide may have resulted in
an increase in total amount of AR agonists in testosterone (0.1 nM)
supplied media to higher levels than in DHT (0.03 nM) supplied
media. However, in clinical practice such a high concentration of
flutamide cannot be achieved, and prolonged exposure to the drug
has resulted in the proliferation of tumour cells that contain a
mutant AR similar to LNCaP cells (Sartor et al, 1994).
We have previously reported that finasteride and some of our
novel compounds may also be acting as anti-androgens against the
LNCaP AR (Klus et al, 1996), and that this may be contributing to
their antiproliferative activities. Moreover, our previous study also
reported that finasteride is only an antagonist of the LNCaP AR
although not of wild-type AR. We evaluated our new azolyl
steroids for possible anti-androgenic effects by treating LNCaP
cells in steroid-free medium with the inhibitors alone. At 5-mM
concentration finasteride inhibited LNCaP cell growth by 25%.
However, the D5NCIs were the most potent inhibitors of cell
proliferation (Figure 4). The order of potency of the compounds
was: VN/85-1 > VN/87-1 > VN/63-1. Cell growth was inhibited
by 70%, 62% and 51% respectively. Similarly, all of the D5NCIs
(5 mM) displaced the synthetic androgen R1881 from LNCaP AR
with a higher potency than finasteride (Figure 5). The order of
potency was VN/63-1 > VN/85-1 > VN/87-1 > finasteride.
Flutamide was again found to stimulate LNCaP cell growth in
steroid-free media by eightfold and the cells responded to the drug
in a biphasic manner. All of the D4NCIs, and high concentrations
of ketoconazole, also stimulated LNCaP cells proliferation (Figure
4). Moreover, the ability of the D4NCIs to displace R1881 from
cellular AR was twofold higher than that of flutamide. The order
of potency was VN/109-1 > VN/107-1 > VN/108-1 > flutamide.
Interestingly, VN/108-1, which is a potent inhibitor of androgen-
induced LNCaP cell proliferation, stimulated cell growth in
absence of androgens, testosterone and DHT. The results presented
here indicate that VN/108-1 is likely to stimulate LNCaP cell
growth through binding to cellular AR. This finding characterizes
VN/108-1 as a partial agonist of LNCaP AR.
In order to determine the effects of our new inhibitors in vivo, we
utilized LNCaP prostate cancer cells grown as tumour xenografts
in male SCID mice (Sato et al, 1997). The effectiveness of the
inhibitors was evaluated by measuring changes in tumour volumes
during a 4-week treatment period. Mice were treated with the
compounds at 50 mg kg–1 day–1, and reference treatments were
castration, ketoconazole and finasteride. VN/109-1 was ineffective
Table 3 Serum levels of testosterone and DHT in male SCID mice following
28 days of treatment with the azolyl steroids and reference drugs
Treatment group Testosterone (ng ml–1) DHT (pg ml–1)
Control 0.205 ± 0.015 239.2 ± 20.5
Castrate 0.054 ± 0.019a 209.8 ± 13.4
Ketoconazole 0.298 ± 0.116 218.0 ± 43.4
Finasteride 0.638 ± 0.453b 223.4 ± 19.6
VN/63-1 0.146 ± 0.035 189.7 ± 17.9
VN/107-1 0.153 ± 0.016 180.2 ± 8.7b
VN/109-1 0.564 ± 0.86b 228.4 ± 42.9
aP < 0.001 versus control; bP < 0.05 versus control.in this model, and moreover it stimulated LNCaP tumour growth
(Figure 7). Although VN/107-1 and VN/108-1 reduced the circu-
lating levels of androgens (Tables 2 and 3), these compounds had
no significant effects on tumour growth or tumour weights (Figures
6 and 7). This implies that androgenic properties of these
compounds outweigh their inhibitory effects on androgen
synthesis. VN/63-1 reduced serum androgen levels, but this reduc-
tion did not gain statistical significance (Table 3) and its growth
inhibitory potency was similar to that of ketoconazole (Figure 7).
VN/85-1 was as effective as finasteride and VN/87-1 was as effec-
tive as castration in inhibiting tumour growth, and both compounds
significantly reduced serum androgen levels (Table 2). Tumour
weights were consistent with the tumour volume data. Tumours
from castrated groups had the lowest weights in both experiments
and were similar to the weights of the tumours in the mice treated
with VN/87-1 and VN/85-1. The anti-tumour effects are consistent
with the activity of these two compounds in other assays. However,
these inhibitors of androgen synthesis were not more effective than
castration at reducing serum androgen levels in the mice (Table 2).
The reason castration was the most effective treatment in this study
is unknown, but the results suggest that factors other than andro-
gens may modulate LNCaP tumour growth in vivo.
PSA is widely used as a marker of prostatic cancer cell prolifera-
tion and, in this model, serum PSA levels were generally correlated
with the weights of the tumours. Surprisingly, serum from the
animals treated with VN/108-1 had the lowest levels of serum PSA
(Figure 6B) and androgens (Table 2), despite the fact that this
compound was ineffective in inhibiting tumour growth. As noted
above, VN/108-1 appears to function as a partial agonist/antagonist
of LNCaP AR. Thus, despite stimulating cell growth, it appears to
down-regulate levels of PSA. Nevertheless, the results obtained
with the reference treatments and novel compounds indicate that
VN/85-1 and VN/87-1 have the most potent anti-tumour activity.
In this report we have described the use of an LNCaP cell
system for evaluating six new inhibitors of P450c17. The
screening protocol presented here demonstrates the useful applica-
tion of the LNCaP prostate cancer cell line for evaluating new
P450c17 inhibitors in vitro and in vivo. This system allows the
evaluation of new compounds for activity against the P450c17
enzyme, their ability to interact with the AR and gives indirect
evidence of activity against 5a-reductase. We have shown that
VN/85-1 and VN/87-1, the most potent P450c17 inhibitors which
are also anti-androgens, have potent anti-tumour effects in male
SCID mice bearing LNCaP xenografts. However, further studies
using other doses of the inhibitors and modes of administration are
necessary to determine fully the usefulness of the compounds.
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